🇺🇸 FDA
Patent

US 7427630

Condensed N-heterocyclic compounds and their use as CRF receptor antagonists

granted A61PA61P1/02A61P1/04

Quick answer

US patent 7427630 (Condensed N-heterocyclic compounds and their use as CRF receptor antagonists) held by Neurocrine Biosciences, Inc. expires Mon Sep 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Sep 23 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P1/02, A61P1/04, A61P1/08, A61P1/14